×
PaxMedica Total Liabilities 2021-2024 | PXMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PaxMedica total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
PaxMedica Total Liabilities 2021-2024 | PXMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PaxMedica total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$142.2B
Bristol Myers Squibb (BMY)
$117.1B
Gilead Sciences (GILD)
$117.1B
Vertex Pharmaceuticals (VRTX)
$105.1B
CSL (CSLLY)
$85.9B
Regeneron Pharmaceuticals (REGN)
$78.5B
GSK (GSK)
$70.5B
Argenex SE (ARGX)
$38B
Alnylam Pharmaceuticals (ALNY)
$31.4B
BioNTech SE (BNTX)
$27.4B
Biogen (BIIB)
$21.7B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$17.7B
Moderna (MRNA)
$15.5B
Genmab (GMAB)
$13.5B
Incyte (INCY)
$13.5B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.6B
Sarepta Therapeutics (SRPT)
$11.6B
Bio-Techne Corp (TECH)
$11.6B
Exact Sciences (EXAS)
$10.8B
Vaxcyte (PCVX)
$10.7B
QIAGEN (QGEN)
$10.3B
Swedish Orphan Biovitrum (BIOVF)
$9.8B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$9B
Roivant Sciences (ROIV)
$8.7B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8.2B